Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent article,, will take times to read and try to digest
Per Chat: The Most up to date Brave Data:
The most up-to-date data on the Brave study is from September 8, 2021. On that date, the study was updated to reflect that it had been completed. However, the study results have not yet been published. The study was designed to evaluate the effectiveness of a text messaging intervention in improving mental health, help-seeking skills, and cultural pride and resilience in Native American teens and young adults. The study enrolled 192 participants, who were randomly assigned to receive either 8 weeks of BRAVE text messages or 8 weeks of Science Technology Engineering and Math (STEM) text messages. The results of the study are not yet available, but the study team has said that they plan to publish them in a scientific journal in the future.
Here are the links to the two clinical trials on the Brave study:
BRAVE Study: Designing and Evaluating Technologies to Promote Adolescent Mental Health https://clinicaltrials.gov/ct2/show/NCT04979481: https://clinicaltrials.gov/ct2/show/NCT04979481
BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) https://clinicaltrials.gov/ct2/show/NCT02398929: https://clinicaltrials.gov/ct2/show/NCT02398929
The BRAVE-EPA study is a Phase 2/3 clinical trial that is investigating the effects of icosapent ethyl (IPE), a prescription-strength fish oil supplement, on the risk of Alzheimer's disease in veterans. The study is being conducted by the Wisconsin Alzheimer's Disease Research Center at the University of Wisconsin-Madison.
The study enrolled 150 cognitively-healthy veterans ages 50-75 years who were at increased risk for Alzheimer's disease due to their combined independent risk factors of parental history of Alzheimer's, increased APOE4 prevalence, and Veteran-related risk factors including high vascular risk profiles, TBI, and PTSD.
Participants were randomly assigned to receive either 4g of IPE or a placebo daily for 18 months. The primary outcome of the study was to measure the effects of IPE on regional cerebral blood flow (rCBF) using arterial spin-labeling MRI. Secondary outcomes included changes in cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, cognitive function, and quality of life.
The study concluded in 2021. The results of the study have not yet been published, but the study team has said that they plan to publish them in a scientific journal in the future.
In the meantime, the study team has released some preliminary data from the study. The preliminary data suggests that IPE may have beneficial effects on rCBF and CSF biomarkers of Alzheimer's disease. However, the study team has cautioned that the preliminary data is not definitive and that more research is needed to confirm the findings.
The BRAVE-EPA study is one of a number of clinical trials that are investigating the potential benefits of omega-3 fatty acids for Alzheimer's disease. Other studies have shown that omega-3 fatty acids may help to improve cognitive function and reduce the risk of Alzheimer's disease. However, more research is needed to confirm these findings and to determine the optimal dose and form of omega-3 fatty acids for the prevention or treatment of Alzheimer's disease.
profile picture
more data
The study was funded by Amarin Corporation, the manufacturer of Vascepa.
The study was designed to be a double-blind, placebo-controlled trial. This means that neither the participants nor the researchers knew who was receiving IPE and who was receiving a placebo.
The study was conducted at 10 sites in the United States.
The primary outcome of the study was to measure the effects of IPE on regional cerebral blood flow (rCBF) using arterial spin-labeling MRI.
Secondary outcomes included changes in cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, cognitive function, and quality of life.
The study concluded in 2021.
The results of the study have not yet been published, but the study team has said that they plan to publish them in a scientific journal in the future.
Here are some of the preliminary data that have been released from the study:
IPE was associated with a significant increase in rCBF in the hippocampus, a region of the brain that is important for memory.
IPE was also associated with a significant decrease in the levels of amyloid beta-42 in the CSF. Amyloid beta-42 is a protein that is associated with Alzheimer's disease.
IPE did not have any significant effects on cognitive function or quality of life.
The study team has cautioned that the preliminary data is not definitive and that more research is needed to confirm the findings. However, the data suggests that IPE may have beneficial effects on rCBF and CSF biomarkers of Alzheimer's disease.
View other drafts
The most up-to-date data on the BRAVE-EPA study is from October 10, 2022. On that date, the study was updated on ClinicalTrials.gov to reflect that it had been completed and that the final data analysis was ongoing. The study team has not yet released any new results from the study, but they have said that they plan to publish a manuscript in a scientific journal in the near future.
In the meantime, the preliminary data that has been released from the study suggests that IPE may have beneficial effects on rCBF and CSF biomarkers of Alzheimer's disease. However, it is important to note that these findings are not definitive and that more research is needed to confirm them.
And the rich get richer, whilst we languish in the doldrums of nothingness
It is great to be back and see positive news!!!!!
Down the toilette.....
Amarin is a "Show Me Company" only sales can drive it!!!!!
Finally, something positive after all of the hardships that traversed our lives with this company... Hopefully full sailing ahead with beautiful sunsets!!!!!
Amarin needs a lot of things...especially a higher stock price!!!!
Thank the previous BOD!!!!!
Biggest bunch of BS that I have ever heard. What ever Denner accomplishes will enhance their accumulated freebies, so they can ride into the sunset quite rich or maybe get on another BOD and try their hands again in diminishing shareholder value........
Loss of freebies is enough....
Amain's BOD got paid for no positive work so who needs em!!!!! Most BOD for major companies reap the benefits at the behest of shareholders....
Someone knows something
Just Voted, got my control $ from E-trade and voted BLUE.....
The've been trying to do that for years
Me thinks that you can call or internet to vote!!!
Thanks, Such BS....Go Blue.....
Just received this from Sarissa rep for proxy cards, I have e-trade
Dear Preston,
Thanks for the email. Sarissa Capital’s proxy statement and blue voting instruction form will be out late this week or early next week. You can vote electronically or via mail by following the instructions on the BLUE voting instructions form sent by E-Trade.
Best,
Michael
From: Preston Moochnek RPh. <massulo@verizon.net>
Sent: Thursday, February 2, 2023 7:26 AM
To: AMRN@dfking.com
Subject: [EXTERNAL] Amarin proxy cards
It's how the new Amarin works!!!!
From de board here me thinks
I keep reading about the new Amarin, where did they come from? What happened to the complacent Amarin that we all grew to hate and despise. Are they shitting in their pants for fear of excoriation from their jobs or that they finally have to work for shareholder?
Anything new would be a thrill IMO
They just did not charge you the copay.. They had to pay for it.. You received a great deal
The combo pack would be a great convenience to patients that have many Rx's
All that they have to prove is that they are cheaper as a compound than 2 separate components IMO. Financial goals are all that are important to them....
I agree and will vote that way too....
No theory, just want to break even make a little and get outta dodge so to speak, Ive been in this when the price was $15 centuries ago, so 10-15 yrs me thinks.......
This is an effort in futility, in my experience the ins. companies will not pay for it. Combo drugs are very rarely paid for especially when its usually cheaper to pay for each drug separately . In this case: Vascepa and whatever generic they choose. Most generic statins now have a ZERO copay( Humana for us). So if Amarin does not raise their prices for the combo over their current rate, it may work...
Thoughts....
Why....He has taken his form 4's and has been absorbed into the feeding tendencies of the BOD...
Better to fly blind than not being able to fly!!!!!
Ill take it!!!!!!!
I love that reasoning........ or maybe he just wants in on the gravy train....LOL
We both have 3, #3 was last month....
It started about 3 in the AM, I was sick as a dog -sore throat , body aching,fever it lasted till mid morning. The severity subsided around noon. Had sinus congestion and plenty of chest congestion.
My wife had it worse. Massive coughing and aching. she lost 10 pounds do to the exertion from all the coughing, I caught it from her!! Both times
Round 2: She ended up in the hospital do to fluctuating PO2 levels, needed O2, not too serious but just being careful. Same symptoms as before.
Me, cough, congestion, malaise etc
We both are triply immunized.
Both trying to forget this episode in our lives.....LOL
You truly do not know if it had any effects on Covid. Remember Covid attacks the circulatory system too. V has an effect on the intima level of the arteries as a stabilizer, so we may never know!!!! I have had Covid 2 times as did my wife!!!
We really do not know what his intentions are as of yet!!!!
For me after all these years seemingly in Amarin"s Jail, just sell the F...ing for $20... and we can all be happy!!!!!!
Can we blame them?
Great study...But would have liked a better P=.031
You got mine....
7 Form 4s...There needs to be a revolt.. These scumsukers need to go to hell
No they do not, I go to CVS on Humana medicare pay 47/month since they lowered the tier level.. There is so much BS out there that its sickening. Blame Amarin BOD for all of this shit.....
They have never tried to substitute..